2,256 results on '"Rizzetto, M."'
Search Results
2. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation
3. 800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma
4. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation
5. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authorsʼ reply
6. MiRNome profiling of circulating extracellular vesicles in patients with chronic hepatitis delta treated with pegylated interferon alpha
7. Oxidative Stress and Cell Damage Following Orthotopic Liver Transplantation.
8. Accumulation of a cellular protein bearing c-myc-like antigenicity in hepatic and non-hepatic delta antigen expressing cells
9. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis
10. Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia
11. Epidemiology of Hepatitis Delta Virus (HDV) Infection
12. Delta Hepatitis Virus Infection in Ethiopia
13. 458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
14. Treatment of chronic hepatitis B: Recommendations from an Italian workshop
15. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries
16. Letter: renal effects of tenofovir in adefovir dipivoxil-experienced HBV patients
17. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
18. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease
19. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study
20. Fatal liver failure following food supplements during chronic treatment with montelukast
21. Endoscopic ultrasound–fine needle aspiration (EUS–FNA) for pancreatic lesions: Effectiveness in clinical practice
22. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
23. Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis
24. Place de l’échoendoscople en Italie
25. Apport de l’écho-endoscopie dans l’hypertension portale
26. Safety and efficacy of twice daily versus every 8 hour Telaprevir with peginterferon/ribavirin (PR) in patients with cirrhosis
27. OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
28. Elevated serum chromogranin A in patients with hepatocellular carcinoma
29. Multicentre retrospective study on endoscopic ultrasound complications
30. Hepatic involvement in larva migrans of Toxocara canis: Report of a case with pathological and radiological findings
31. Emergency catheter probe endoscopic sonography (CP-EUS): An effective procedure in the assessment of a bleeding gangliocytic paraganglioma
32. Severe steroid-unresponsive ulcerative colitis: Outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment
33. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
34. Diagnosis of deep-seated lymphomas by endoscopic ultrasound-guided fine needle aspiration combined with flow cytometry
35. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
36. Acute myocardial infarction andHelicobacter pylori seropositivity
37. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*
38. Thymalfasin in the treatment of hepatitis B and C
39. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
40. Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and chronic hepatitis C: 425
41. Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study: 410
42. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications
43. Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay
44. A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin
45. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations
46. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study
47. Evidence of a dynamic aldosterone-independent distal tubular control of renal sodium excretion in compensated liver cirrhosis
48. Treatment of hepatitis D
49. The use of the anti-tumour necrosis factor monoclonal antibody—infliximab—to treat ulcerative colitis: implications and trends beyond the available data
50. AISF position paper on HCV in immunocompromised patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.